Coriolis Pharma Appoints Dr. Teun van der Heide as Chief Executive Officer

Coriolis Pharma Appoints Dr. Teun van der Heide as Chief Executive Officer

New CEO to drive the company’s next phase of global growth

Martinsried, Germany / Durham, NC, USA, November 2, 2026 – Coriolis Pharma, a leading partner for the research and development of biopharmaceutical medicines, today announced the appointment of Dr. Teun van der Heide as Chief Executive Officer (CEO), effective November 2, 2026.

Dr. van der Heide brings extensive leadership and commercial experience in the pharmaceutical and life sciences industries. His career includes senior positions at Lonza, where he headed the business units Bioscience Solutions and Capsule Delivery Solutions (Capsugel), and most recently at ten23 health, where he served as Chief Business Officer (CBO), overseeing the company’s business development and commercial activities.

Drawing on his industry expertise, commercial leadership, and deep understanding of the CDMO industry, Dr. van der Heide will focus on strengthening customer relationships, maintaining high service quality, unlocking new growth opportunities, and further expanding Coriolis Pharma’s global presence, particularly in the United States.

“We are delighted to welcome Teun to Coriolis Pharma”, said Dr. Michael Wiggenhorn, Co-Founder and Board Member, Coriolis Pharma. “His industry experience, entrepreneurial mindset, and proven commercial leadership, particularly as Chief Business Officer at ten23 health, make him exceptionally well positioned to strengthen our business and drive our next phase of growth in Europe, the United States, and beyond.”

Dr. Wiggenhorn added: “We also sincerely thank Silvia Steyrer-Gruber for her leadership and contributions to Coriolis Pharma over the past four and a half years and wish her all the best for the future.”

End of Press Release